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Abstract
Background: Cavernous hemangiomas are the most frequent neoplasms of the liver and in routine clinical
practice they often need to be differentiated from malignant tumors and other benign focal lesions. The purpose
of this study is to evaluate whether diagnostic accuracy of magnetic resonance imaging (MRI) of hepatic
hemangiomas, showing atypical pattern on US, improves with the use of Gd-BOPTA in comparison with contrast-
enhanced multi-phase computed tomography (CT).
Methods: 178 consecutive patients with ambiguous hepatic masses showing atypical hyperechoic pattern on grey-
scale US, underwent unenhanced and contrast-enhanced multi-phase multi-detector CT and MR (1.5T) with the use
of liver-specific contrast medium gadobenate dimeglumine (Gd-BOPTA). After intravenous contrast administration
arterial (HAP), venous-portal (PVP), equilibrium phases (EP) both in CT and MR and additionally hepatobiliary phase
(HBP) in MR were obtained. 398 lesions have been detected including 99 hemangiomas and 299 other lesions.
Results: In non-enhanced MDCT examination detection of hemangiomas was characterized by sensitivity of 76%,
specificity of 90%, PPV of 71%, NPV of 92% and accuracy of 86%.
Non-enhanced MR examination showed sensitivity of 98%, specificity of 99%, PPV of 99%, NPV of 99% and
accuracy of 99%.
After intravenous administration of contrast medium in MR the mentioned above parameters did not increase
significantly.
Conclusion: Gd-BOPTA-enhanced MR in comparison with unenhanced MRI does not improve diagnostic accuracy
in discriminating hemangiomas that show non-specific appearance in ultrasound examination. Unenhanced MR as
a method of choice should directly follow US in course of diagnostic algorithm in differentiation of hemangiomas
from other liver tumors.
Background
Cavernous hemangiomas are the most frequent benign
neoplasms of the liver, found in autopsy examinations
within 0.4% to 20% of population [1,2]. Such frequent
occurrence of hepatic hemangiomas (HH) rises a need
for differential diagnosis between those benign lesions
and malignant liver tumors, especially metastases. Many
HH show characteristic image in US examination. How-
ever, in some cases hemangiomas show a non-specific
appearance in baseline B-mode US [3,4] and contrast-
enhanced ultrasound (US), computed tomography (CT)
or magnetic resonance (MR) examinations are applied
for further evaluation of observed focal liver lesions. An
atypical hemangioma in US usually shows echogenic
border, internal echogenic pattern at least partially
hypoechogenic, totally hypoechogenic or heterogenic
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lesion [5].
Great technological development concerning both
multi-detector computer tomography and hepatocyte-
specific contrast agents in magnetic resonance imaging
(MRI) has been observed in recent years.
Computed tomography is a well established procedure
of imaging of hepatic hemangiomas. Most hemangiomas
show typical enhancement pattern: nodular or globular
peripheral enhancement in arterial phase with a progres-
sive fill-in in portal venous and equilibrium phases.
In particular cases the use of magnetic resonance ima-
ging leads to specification of diagnosis based on US and
CT findings.
Many studies have been dedicated to differential diag-
nosis of hemangiomas from malignant tumors [6-8].
Previous studies showed that the use of hepatocyte-spe-
cific contrast agents improves the accuracy and confi-
dence of diagnosis of focal liver lesions, however, to our
best knowledge none compared gadobenate dimeglu-
mine (Gd-BOPTA) enhanced MRI with unenhanced
MR and CT in differentiation of hemangiomas showing
atypical US appearance from other focal liver lesions
[9,10]. Any imaging technique used for verification of
atypical hemangiomas should be validated.
T h ep u r p o s eo ft h i ss t u d yi st oe v a l u a t ew h e t h e r
assessment by means of MRI of hepatic hemangiomas,
showing atypical appearance on gray-scale US, improves
with the use of Gd-BOBTA in comparison with con-
trast-enhanced multiphase CT.
Methods
178 consecutive patients with non-specific hepatic foci
observed in US were included in this prospective study
and spiral CT and MR examinations were performed in
those patients within the period not exceeding 3 weeks.
Inclusion criteria were as follows: presence of focal liver
lesion that in grey-scale US did not present typical features
of a simple cyst (anechoic focus with posterior acoustic
enhancement) or a typical hemangioma (hyperechoic oval
pattern with homogeneous or slightly inhomogeneous
echotexture, well-defined margins and posterior wall sha-
dowing, figure 1a). The atypical hemangiomas included in
the study were characterized on US by echogenic border,
internal echogenic pattern at least partially hypoechogenic
or totally hypoechogenic pattern (figure 1b, c).
Exclusion criteria included any contraindications to
CT or MR examination, amongst them contraindica-
tions to iodine contrast agents or Gd-BOPTA adminis-
tration and lack of patient’s consent.
The standard of reference was the histopathological
examination or clinical and imaging follow-up for the
duration of 18 months in case of HH and FNH, 12
months in case of inflammatory lesions and 3 to 24
months in patients suffering from liver metastases trea-
ted with chemotherapy.
MR study was performed with 1.5 T MR system using
phased-array flex coil. The protocol included: T1-
weighted SE sequence (TR/TE ms - 303/12, scan time -
17sec) in axial and coronal plane with and without con-
trast enhancement in equilibrium and hepatobiliary
phase, T2-weighted Express sequence (18000/92, scan
time - 17sec) in axial plane, T2-weighted FSE (6500/
116.8, scan time - 20sec) in coronal plane, performed
also with fat saturation and T1-weighted out of phase
sequence (150/2.24, flip angle of 90°, scan time - 12sec)
without and after contrast administration in hepatic
arterial dominant phase (HAP), portal venous dominant
phase (PVP), equilibrium phase (EP) and hepatobiliary
phase (HBP). Slice thickness was 5mm, intersection gap -
0.5, matrix 256 × 256. Dynamic MRI was obtained imme-
diately after a bolus injection of Gd-BOPTA (dosage of
0.1 mmol per kilogram of body weight), followed by sal-
ine solution flush of 25mL through a 20G venous cathe-
ter positioned in the antecubital vein. Similarly to the
multiphase CT study HAP, PVP, and EP were performed
after respectively 25, 60 and 180sec. HBP was acquired
60min after contrast agent administration. The phase-
encoding direction was anterior-posterior for all
sequences. All images were acquired during breath-hold.
Figure 1 Hepatic hemangioma in US. Transverse sonogram of left lobe of liver presents typical hyperechogenic hemangioma (a). Figure 1b
and c show two different hypoechogenic liver lesions suspected to be atypical hemangioma, subsequently confirmed in CT.
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Page 2 of 10Multi-phase multi-detector (6 and 32-row) CT exami-
nation of the liver has been conducted first unenhanced,
then after application of a contrast agent in HAP, PVP
and EP. 100ml of iodinated contrast agent at a rate of
4mL/sec through an 20G venous catheter positioned in
an antecubital vein using a power injector was admini-
strated. The CT section thickness was 2.5mm, images
interval - 2.5mm and pitch - 1.0.
Spiral CT and MRI were then interpreted by three
independent radiologists with at least 10-years (ES, MS)
and 5-years (AS) experience in abdominal imaging, who
had no previous knowledge of patients’ medical history.
The interval between CT and MR examinations was
from 3 to 5 weeks. Final assessment was based on the
observers’ consensus in case of disagreement.
Radiological parameters assessed in CT and MR analy-
sis were: size of detectable lesions, their density, signal
intensity and type of enhancement.
Signal intensity of each lesion in relation to adjacent
liver parenchyma in T2-weighted TSE images was
assessed. A 4-point scale has been used: 1-hypointense,
2-isointense, 3-hyperintense and 4-bright lesion (marked
hyperintensity, figure 2).
Type of enhancement in hepatic arterial phase was
qualified as one of the following: intensive homoge-
nous, heterogenous, nodular or globular peripheral
enhancement, partial or complete ring shape and no
enhancement.
In portal venous and equilibrium phase one of the fol-
lowing enhancement type was assigned to each visible
lesion: homogenous, heterogenous, progressive fill-in,
partial or complete ring shape, no enhancement and
enhancement similar to liver.
Each focus was assessed by independent observers in
MDCT, unenhanced MRI and Gd-BOPTA-enhanced
MRI and classified into one of the groups: hemangioma
or non-hemangioma.
In unenhanced MRI hemangioma was defined as a
lesion presenting low signal intensity in T1-weighted
images, while in T2- and heavily T2-weighted images
remaining highly homogenous, clearly demarcated from
the adjacent liver parenchyma, showing very high signal
intensity, similar to that of cerebrospinal fluid, due to
the long T2 relaxation time of its blood-filled vascular
channels. This feature has been described as the bulb-
light sign.
In dynamic contrast-enhanced CT and MRI heman-
giomas were defined when showing peripheral globular
enhancement and a centripetal fill-in pattern with the
attenuation of enhancing areas corresponding to that of
the aorta and blood pool.
Hemangiomas were diagnosed in Gd-BOPTA-
enhanced MRI when showing typical features of heman-
gioma in unenhanced-MRI and/or in dynamic contrast-
enhanced MR examination.
These criteria have been previously applied by many
authors [11-14].
Foci were evaluated as of a different type than heman-
giomas when not presenting any of the above mentioned
features.
All lesions were divided into two groups: the first
group (HH group) consisted only of liver hemangiomas,
the second group (nonHH group) included focal liver
lesions other than hemangiomas.
All lesions were also classified as small or large
according to their medians by the study coordinator
(ES).
The interobserver agreement was measured with
Cohen’s kappa coefficient. Statistical analysis of size of
detectable lesions, their density, signal intensity and
type of enhancement of hemangiomas and other
lesions in unenhanced, gadolinium-enhanced MR and
CT studies has been performed with Statistica 8 soft-
ware (StatSoft Inc., Tulsa, OK, USA) and McNemar’s
test with Bonferroni correction for multiply compari-
son. P values less than 0.05 were considered as statisti-
cal significant.
Figure 2 Hepatic hemangioma. Moderately (a) and heavily (b) T2-
weighted MR images show typical bright lesions.
Szurowska et al. BMC Gastroenterology 2011, 11:43
http://www.biomedcentral.com/1471-230X/11/43
Page 3 of 10The research was approved by Independent Bioethic
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of Gdansk (NKEBN/649/2001-2002). All patients gave
their written consent to participate.
The study has been partially financed from the
research grant ST-82 given by authorities of the Medical
University of Gdansk to MS.
Results
178 patients were qualified for the study, amongst this
group 161 underwent further analysis (95 women and
66 men, age 18-79 years).
In case of 17 patients we failed to establish the final
diagnosis - 2 of the patients passed away, 15 did not
show for the follow-up.
High interobserver agreement (kappa values of 0.80-
0.99) confirmed the methodology as reliable and
reproducible.
In 100 patients the final diagnosis was based upon his-
topathological examination results (66 cases by the
means of surgery and 34 cases with biopsy) which dis-
closed: 41 cases of HCC, 21 FNHs, 28 cases of liver
metastases, 4 cavernous hemangiomas, 4 solitary adeno-
mas and 2 cases of peripheral cholangiocarcinoma.
In the remaining 61 patients, the final diagnosis was
based upon the clinical and diagnostic imaging follow-
up. In this group we observed: 30 hepatic hemangiomas
(confirmed in contrast-enhanced US examination and
follow-up MR examination), 18 FNHs (confirmed in
Gd-EOB-DTPA-enhanced MR), 13 cases of liver metas-
tases (treated with chemotherapy and confirmed in fol-
low-up CT examinations) and 2 inflammatory lesions
(follow-up CT examinations showed no lesions).
The HH group consisted of 99 liver hemangiomas,
recognized in 34 patients. 21 patients with HH had iso-
lated liver lesions and multifocal HHs were recognized
in 13 people.
The nonHH group included 127 patients with 299
focal liver lesions other than hemangioma: 144 metas-
tases, 100 cases of hepatocellular carcinoma, 4 adeno-
mas, 44 FNHs and 7 other lesions.
The diameter of foci ranged from 6mm to 125mm
(median 21mm). According to the mean foci diameter,
all lesions were divided into two groups: small lesions
(<2cm) - 199 foci and large lesions (≥2cm) - 199 foci. In
the HH-group, 40 foci of cavernous hemangiomas were
large lesions and the rest of 59 tumors were small
lesions.
Small hemangiomas more frequently (30/59) showed
homogenous enhancement pattern in all three phases,
while large hemangiomas (25/40) presented nodular or
globular peripheral enhancement pattern in HAP and
progressive fill-in in PVP and EP in dynamic MR study
(table 1). The type of enhancement in consecutive
phases was completely the same in both CT and MR
studies.
Gd-BOPTA - enhanced MR and multi-phase spiral
CT evaluation of hepatic hemangiomas was based upon
typical enhancement pattern in three phases (table 2):
- homogenous in HAP and PVP or EP (figure 3),
- nodular peripheral or globular in HAP with
progressive fill-in enhancement in PVP and EP
(figure 4).
In the hepatobiliary phase of MR examination all
hemangiomas showed a lower signal in comparison to
the adjacent liver tissue (figure 5). 233 nonHH lesions
were hypointense, 63 isointnese and 3 hyperintense.
Spiral CT correctly characterized 75 hemangiomas.
Signal intensity observed in moderately and heavily
T2-weighted images in hemangiomas and other liver
lesions is presented in table 3.
In unenhanced MR false-negative diagnosis was
obtained in one case of hemangioma and one false-posi-
tive diagnosis of hemangioma was noted in case of cys-
tic metastasis from ovarian carcinoma.
Gd-BOPTA-enhanced MR study allowed to correctly
diagnose cystic metastasis from ovarian carcinoma and
therefore revealed 98 hemangiomas. Still one heman-
gioma was unrecognized (figure 6).
Unenhanced MR and Gd-BOPTA-enhanced MR show
higher diagnostic accuracy in differentiation of heman-
giomas than CT (p < 0.0001 for both modalities), also in
case of small (p < 0.0001 for both modalities) and large
lesions assessed separately (p = 0.0055 for unenhanced
MR and p = 0.0009 for Gd-BOPTA-enhanced MR).
No statistically significant difference in diagnostic effi-
cacy between unenhanced MR and Gd-BOPTA-
enhanced MR has been showed.
Table 1 Relation between the enhancement pattern and
detectable lesions in HAP and PVP in three groups:
small, large and all lesions
HH nonHH
small large all size small large all size
HAP homogenous 30 11 41 46 16 62
heterogenous 1 2 3 1 19 20
nodular peripheral 9 25 34 4 7 11
ring shape 10 1 11 77 93 170
no enhancement 9 1 10 12 24 36
PVP homogenous 32 11 43 16 9 25
heterogenous 1 1 2 2 10 12
progressive fill-in 9 25 34 2 4 6
ring shape 4 1 5 67 81 148
similar to liver 13 2 15 53 55 108
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unenhanced versus gadolinium-enhanced MR and CT
imaging in the characterization of liver hemangiomas
are shown in table 4.
Discussion
Differentiation between hemangiomas and malignant
liver lesions is an important clinical problem both in
patients with known malignancy as well as in cases of
incidentally detected hepatic lesions.
The diagnosis of hemangiomas relies mainly on the fol-
lowing parameters: hyperechogenicity in ultrasound, typical
enhancement pattern in CT or MR images (nodular per-
ipheral in HAP with progressive fill-in in PVP and in EP)
and high signal intensity in T2-weighted images [11-14].
In dynamic examination the enhancement pattern of
hemangiomas does not differ in neither CT nor MR
study.
Distinction between metastases and cavernous heman-
giomas on the basis of different patterns of enhance-
ment is well described, but to our knowledge, only few
reports focus on the type of enhancement, diagnosed
with hepatocyte-specific contrast-enhanced MRI [15].
In presented study the assessment of focal lesions in
MR was performed with the use of moderately and
heavily T2-weighted sequences and dynamic examina-
tion after Gd-BOPTA administration.
Ultrasound was the initial examination qualifying
patients into this study as it allowed to distinguish a
group of patients with ambiguous focal liver lesions,
some of suspected malignant nature.
Patients presenting lesions of typical ultrasound
appearance of hemangiomas and simple cysts were
excluded from further studies as such lesions may be
successfully monitored in grey-scale ultrasound
examinations.
To assess foci in moderately T2-weighted images qua-
litative criteria proposed by Fenlon were used [16].
In moderately T2-weighted images, foci of markedly
high signal intensity (so called bright lesions) were clas-
sified as hemangiomas (figure 2), assuming that they
were homogenous. Lesions with a visible central necro-
sis were treated as heterogenous and changes in signal
characteristics were referred to tissue elements on their
periphery. Usefulness of T2-weigthed images for diagno-
sis of hemangiomas is already well known [7,17-23].
A high diagnostic efficacy of marked hyperintensity in
moderately and heavily T2-weighted images as a feature
allowing to diagnose hepatic hemangiomas was proven
with indexes of diagnostic efficacy reaching 99% (table 4).
Similar observation was made by Ito et al. [17], who
gained 100% efficacy in discriminating hemangiomas
smaller that 3cm in diameter and McFarland et al., who
reported that dual-echo heavily T2-weighted sequence
(TE = 80, 160ms) allows to distinguish hemangiomas
from malignant neoplasms with 100% sensitivity and
92% specificity [18] due to their highly hyperintense sig-
nal in T2-weighted images, described as the bulb-light
sign [24-26].
Fenlon et al. compared qualitative and quantitative
analysis of hepatic tumors using heavily T2-weighted SE
technique and they noted that quantitative method with
measurement of T2-relaxation times allowed signifi-
cantly better differentiation between benign and malig-
nant neoplasms with accuracy about 100% than that of
the subjective visual assessment of focal liver lesions
[16].
In our series a false-negative diagnosis concerned one
case of hemangioma with areas of fibrosis and hyaliniza-
tion, which mimicked a solid part of malignant necrotic
neoplasm. One false-positive diagnosis of hemangioma
was reported in case of cystic metastasis from ovarian
cancer. We did not observe characteristic strong hyper-
intensity typical for hemangiomas in other cases of
malignant tumors especially in necrotic or hypervascular
metastases as noted in literature [27,28].
Table 2 Relation between typical enhancement pattern for hemangioma in successive phases of dynamic CT/MR
studies (homogeneous enhancement in HAP, PVP and EP or nodular peripheral/globular enhancement in HAP with
progressive fill-in enhancement in PVP and EP) and detectable lesions in three groups: small, large and all lesions
Groups and
subgroups
Homogeneous enhancement in HAP, PVP
and EP (number of foci)
Nodular peripheral/globular enhancement in HAP with progressive fill-in
enhancement in PVP and EP (number of foci)
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Page 5 of 10The next radiological feature that allows recognition
of HH is the type of enhancement observed in succes-
sive phases of dynamic CT or MR examination after
extracellular iodine or gadolinium based contrast med-
ium administration. Ros et al. [29] distinguished three
types of enhancement in liver hemangiomas according
to their diameter:
- early homogenous enhancement seen in foci of less
than 1.5 cm in diameter,
- nodular peripheral enhancement in HAP with a
progressive centripetal fill-in pattern, to homogenous
enhancement in the late phase (foci from 1.5 to 5cm
in diameter),
- nodular peripheral enhancement in HAP with a
hypointense center of the lesion in the late phase
(foci larger than 5 cm in diameter).
Essentially in our study two types of enhancement
patterns in HAP were stated: nodular peripheral and
homogenous (table 1). At the same time correlation
between type of enhancement and size of lesion was
noted (table 2). In small hemangiomas, homogenous
enhancement pattern was observed in HAP, PVP and
EP phases in CT and MR studies. This finding was also
reported by other authors [30-34] in MR examination
and described as flash-filling pattern.
In hemangiomas greater than 2cm in diameter a nod-
ular peripheral enhancement pattern in HAP with pro-
gressive slow centripetal fill-in during next phases has
been observed. This type of enhancement has been
described as specific for hemangiomas since 1986
[35-37].
The value of PPV and accuracy and sensitivity in dif-
ferentiation of hemangiomas from other focal liver
lesions based of enhancement pattern presented in
multi-phase sCT study are 0.71, 0.86 and 0.76 and
noticeably lower than all indexes of diagnostic efficacy
obtained by using unenhanced-MRI (PPV-0.99). In the
group of lesions smaller than 2cm, sensitivity of diag-
nostic methods based on contrast CT enhancement pat-
tern is even lower, at the range of 0.66.
Presented study in accordance to the other authors
[30,38] shows that nodular peripheral enhancement pat-
tern allows discrimination of larger hemangiomas, while
it has no application in differentiating small lesions.
In this study all hemangiomas presented weaker
enhancement in hepatobiliary phase in comparison to
the adjacent liver parenchyma, similarly to metastases
and the majority of HCCs. This results from the charac-
teristic of applied hepatocyte-specific contrast media -
Gd-BOPTA. Gadobenate dimeglumine (Gd-BOPTA) is
a gadolinium-based paramagnetic contrast with a vascu-
lar-interstitial distribution during first few minutes. The
majority of this contrast agent is excreted by the kid-
neys in the urine, however, about 4% of the injected
dose is taken up by the hepatocytes and eliminated via
anionic transporter across the sinusoidal membrane into
the bile [39].
Figure 3 Hepatic hemangioma. MR study presents a
homogeneous pattern of enhancement clearly visible in hepatic
arterial (a) and portal venous (b) phases. T2-weighted MR image
shows typical radiological finding of hemangioma - marked
hyperintensity (c).
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Page 6 of 10Due to contrast agent presence within hepatic cells, it
is possible to observe the enhancement of the liver par-
enchyma that persists for 1-3 hours after its administra-
tion and this period is called hepatobiliary phase.
A tumor that does not contain functioning hepato-
cytes in which hepatobiliary metabolism is active, is not
able to uptake Gd-BOPTA.
Hemangiomas consist of multiple vascular channels
limited by single layer of endothelial cells within a thin
fibrous stroma and the enhancement in hepatobiliary
phase is not observed, what makes hemangiomas impos-
sible to differentiate from other hepatocyte-devoided
liver tumors [25,40,41].
Main restrictions of this study are a small number of
cases of hemangiomas confirmed in histological exami-
nation, lack of quantitative analysis of focal liver lesions
signal intensity as described by other authors [42] and
Figure 4 T h es a m ec a s eo ft h eh e p a t i ch e m a n g i o m aa si nf i g u r e2 . HAP-CT image clearly visualizes globular type of enhancement (a).
Globular pattern of enhancement is also visible in HAP - MR image (b). Progressive fill-in enhancement pattern can be observed in PVP (c) and
EP (d) phases of MR study.
Figure 5 The same case of the hepatic hemangioma as in
figures 2 and 4 . Hepatobiliary phase in MR presents weaker
enhancement of this lesion in comparison to the adjacent liver
parenchyma.
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Page 7 of 10Table 3 Relation between signal intensity in moderately and heavily T2-weighted images and type of detectable
lesions in three groups: small, large and all lesions
signal intensity in moderately and heavily T2-weighted images of all lesions
hypointense isointense hyperintense markedly hyperintense
small HH 0 0 0 59
small nonHH 19 52 69 0
large HH 0 0 1 39
large nonHH 10 34 114 1
all size HH 0 0 1 98
all size nonHH 29 86 183 1
Figure 6 Hepatic hemangioma with atypical enhancement pattern in dynamic MR study. Moderately T2-weighted MR image with
untypical weak intensity of the lesion (a). In HAP (b) enhancement of the hemangioma is not visible. Figure 6c shows central enhancement of
the lesion in EP. The hemangioma presents weaker enhancement than the adjacent liver parenchyma in hepatobiliary phase (d).
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Page 8 of 10no incidence of giant hemangiomas (>8cm) in which
secondary changes like hemorrhage or hyalinization are
more frequent [43].
Our results indicate that qualitative analysis of signal
intensity of hepatic lesions in moderately and heavily
T2-weighted images is the most sensitive method of dif-
ferentiation between liver hemangiomas of non-specific
appearance in ultrasound from malignant tumors.
Assessment of the enhancement pattern provides infor-
mation about vascularity of the lesion although the type
of enhancement pattern itself is not as important in
characterization of hemangiomas as the intensity of the
lesion in T2-weighted images.
Application of contrast-enhanced MR, especially with
administration of liver-specific contrast agents in diagnos-
ing liver hemangiomas is not advisable as it leads to elon-
gation of examination time and unnecessary exposure to
potential side effects of intravenous contrast agents.
Conclusion
Gd-BOPTA-enhanced MR in comparison with unen-
hanced MRI does not improve diagnostic accuracy in
discriminating hemangiomas that show non-specific
appearance in ultrasound examination. Unenhanced MR
as a method of choice should directly follow ultrasound
examination in course of diagnostic algorithm in differ-
entiation of hemangiomas from other liver tumors.
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